Andina Acquisition Corp. III
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Andina Acquisition Corp. III operates as a special purpose acquisition company (SPAC) primarily focused on effecting business combinations, mergers, or acquisitions. Founded in 2016 and headquartered in Bogotá, Colombia, the company aims to engage in the manufacturing, marketing, and sale of healthy snack products. Its core business activity transitioned significantly following its 2021 business combination with Stryve Foods, LLC, a U.S.-based healthy snacking platform specializing in air dried meat snacks. The combination involved Andina's re-domiciliation from the Cayman Islands to Delaware and its renaming to Stryve Foods, Inc., which now trades on the NASDAQ under the ticker SNAX. The combined entity focuses on the development and distribution of differentiated healthy snack products, leveraging Stryve’s expertise in functional and nutritious meat snacks with a presence primarily in the United States. The transaction included a concurrent private placement raising approximately $53.4 million, facilitating accelerated growth and expansion of product offerings and distribution channels. Key recent strategic moves include deepening market penetration through expanded SKUs, scaling e-commerce operations, and investing in vertical integration and infrastructure to support growth. The company stands as a leader in disrupting traditional snacking categories through innovative healthy snack options, targeting health-conscious consumers in North American markets.
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Hikma acquires Novugen's FDA-approved ANDA for trametinib
Andina Acquisition Corp. III and Stryve Foods LLC Announce Shareholder Approval of the Business Combination
SHAREHOLDER ALERT: WeissLaw LLP Reminds VKIN, CLGX, VGAC, and ANDA Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: WeissLaw LLP Investigates Andina Acquisition Corp. III
Andina Acquisition Corp. III and EMMAC Life Sciences Limited Announce Termination of Negotiations
Andina Acquisition Corp. III Announces Adjournment of the Extraordinary General Meeting of Shareholders for Approving an Extension of the Deadline Related to Consummating its Initial Business Combination
Andina Acquisition Corp. III Announces Intention to Adjourn Extraordinary General Meeting of Shareholders for Approving an Extension of the Deadline Related to Consummating its Initial Business Combination
Andina Acquisition Corp. III and EMMAC Life Sciences Limited Provide Update on Status Towards Signing Business Combination Agreement
Andina Acquisition Corp. III Rights And Warrants: Whether 3rd Time Will Be A Charm By October 31, 2020
Embotelladora Andina SA ADR Series A (AKO.A) Scheduled to Post Quarterly Earnings on Tuesday
Embotelladora Andina SA ADR Series A (NYSE:AKO.A) Stock Price Passes Below Two Hundred Day Moving Average of $13.79
Embotelladora Andina SA ADR Series A (NYSE:AKO.A) Share Price Passes Below 200 Day Moving Average of $14.02
Edited Transcript of AC*.MX earnings conference call or presentation 25-Oct-19 3:00pm GMT